Lataa...

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()

BACKGROUND: Ectopic pregnancies are a leading cause of maternal mortality. Most are treated surgically. We evaluated the efficacy and safety of combining oral gefitinib (epidermal growth factor receptor inhibitor) with methotrexate to treat larger ectopic pregnancies. METHODS: We performed a phase I...

Täydet tiedot

Tallennettuna:

Bibliografiset tiedot
Julkaisussa:	EBioMedicine
Päätekijät:	Skubisz, Monika M., Tong, Stephen, Doust, Ann, Mollison, Jill, Johns, Terrance G., Neil, Peter, Robinson, Miranda, Bhattacharya, Siladitya, Wallace, Euan, Krzys, Nicole, Colin Duncan, W., Horne, Andrew W.
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2018
Aiheet:	Research Paper
Linkit:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6085507/ https://ncbi.nlm.nih.gov/pubmed/29941341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2018.06.017
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()

Samankaltaisia teoksia

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()